12:00 AM
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ARN-509: Phase I/II data

Data from the Phase I portion of an open-label, dose-escalation Phase I/II trial in 24 patients with progressive metastatic CRPC showed that 30-300 mg doses of oral ARN-509 given on a continuous daily dosing schedule were well tolerated with fatigue, nausea...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >